Petal Consortium

Jain Lab

About Us

Study Details

News Center

For Healthcare Professionals

Participating Centers

Support Us

Jain lab

Publications

February, 2025

Our article with the PETAL consortium titled Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: results from the PETAL consortium was featured in Blood Advances Highlights on February 18th!

We are excited to share this editorial on our Blood Advances paper PETAL: a global view on R/R T-/NK-lymphoma treatment reality

American Society of Haematology Conference 2024

The Jain Lab T Cell Lymphoma program was invited to give an oral presentation on the PETAL Consortium’s novel PIRT scoring tool. In addition, three poster presentations were given and are listed below. We are extremely excited for our team and their wonderful accomplishments!

Oral presentations

Development of a Novel Prognostic Score for Relapsed/Refractory Mature T-Cell and NK-Cell Lymphomas (PIRT): Results from a Global Peripheral T-Cell Lymphoma (PETAL) Consortium

Angela Koh

Development of a Novel Prognostic Score for Relapsed/Refractory Mature T-Cell and NK-Cell Lymphomas (PIRT): Results from a Global Peripheral T-Cell Lymphoma (PETAL) Consortium

Angela Koh

Development of a Novel Prognostic Score for Relapsed/Refractory Mature T-Cell and NK-Cell Lymphomas (PIRT): Results from a Global Peripheral T-Cell Lymphoma (PETAL) Consortium

Angela Koh

B. Poster presentations

Unveiling the Tumor Microenvironment in Extranodal NK/T-Cell Lymphoma (ENKTCL) Patients with in Situ Spatial Transcriptomics

Dimitra Karagkouni

Unveiling the Tumor Microenvironment in Extranodal NK/T-Cell Lymphoma (ENKTCL) Patients with in Situ Spatial Transcriptomics

Dimitra Karagkouni

Unveiling the Tumor Microenvironment in Extranodal NK/T-Cell Lymphoma (ENKTCL) Patients with in Situ Spatial Transcriptomics

Dimitra Karagkouni

Real-World Evidence for Duvelisib and Romidepsin Combination in Patients with Relapsed/Refractory Peripheral T-Cell Lymphomas

Josie Ford

Real-World Evidence for Duvelisib and Romidepsin Combination in Patients with Relapsed/Refractory Peripheral T-Cell Lymphomas

Josie Ford

Real-World Evidence for Duvelisib and Romidepsin Combination in Patients with Relapsed/Refractory Peripheral T-Cell Lymphomas

Josie Ford

Integrative Analysis of 3D Chromatin Organization Revealed Regulation Mechanisms in Angioimmunoblastic T-Cell Lymphoma

Makoto Iwasaki

Integrative Analysis of 3D Chromatin Organization Revealed Regulation Mechanisms in Angioimmunoblastic T-Cell Lymphoma

Makoto Iwasaki

Integrative Analysis of 3D Chromatin Organization Revealed Regulation Mechanisms in Angioimmunoblastic T-Cell Lymphoma

Makoto Iwasaki

October, 2024

Another great milestone achieved for PETAL as our paper, “Global Outcomes and Prognosis for Relapsed/Refractory Mature T-Cell and NK-Cell Lymphomas: Results from the PETAL Consortium,” has been accepted for publication in Blood Advances, the open-access journal of the American Society of Hematology.

Congratulations to Makoto Iwasaki, MD, PhD, on receiving the esteemed ASH Global Research Award from the American Society of Hematology (ASH) with the support of Caroline MacVicar! This award will support his research in developing machine learning models to predict T-cell lymphoma outcomes.

Makoto Iwasaki

Congratulations to Shambhavi Singh, MD, PhD, for being selected as a recipient of the 2024 ASH Hematology Opportunities for the Next-Generation of Research Scientists (HONORS) Award.

Shambhavi Singh

Congratulations to Shambhavi Singh, MD, PhD, for being selected as a recipient of the 2024 ASH Hematology Opportunities for the Next-Generation of Research Scientists (HONORS) Award.

Shambhavi Singh

Congratulations to Shambhavi Singh, MD, PhD, for being selected as a recipient of the 2024 ASH Hematology Opportunities for the Next-Generation of Research Scientists (HONORS) Award.

Shambhavi Singh

June 2024

T-cell Lymphoma Forum (TCLF) 2024

The Jain Lab T-cell lymphoma program was invited to give 2 oral presentations and 3 poster presentation on their global PETAL consortium - an incorporation of novel machine learning strategies to estimate patient outcomes for peripheral T-cell lymphoma.

Oral presentations

Global patterns of care in PTCL, Presented by: Salvia Jain

Dr Salvia Jain

Global patterns of care in PTCL, Presented by: Salvia Jain

Dr Salvia Jain

Global patterns of care in PTCL, Presented by: Salvia Jain

Dr Salvia Jain

Incorporation of Novel Causal Inference Methods to Define Impact of Therapy Sequences in Relapsed and Refractory Mature T- and NK-Cell Neoplasms: A Global Study of the PETAL Consortium, Presented by: Mark N Sorial

Mark Sorial

B. Poster presentations

Integrated Omics to Dissect the Landscape in Chemosensitive and Refractory Extranodal Natural-Killer T-Cell Lymphoma (ENKTCL): A Global Study of the PETAL (Peripheral T-Cell Lymphoma) Consortium, Presented by: Sean M McCabe

Sean McCabe

Integrative analysis of 3D chromatin organization reveals regulation mechanisms in angioimmunoblastic T-cell lymphoma, Presented by: Caroline MacVicar

Caroline MacVicar

Integrative analysis of 3D chromatin organization reveals regulation mechanisms in angioimmunoblastic T-cell lymphoma, Presented by: Caroline MacVicar

Caroline MacVicar

Integrative analysis of 3D chromatin organization reveals regulation mechanisms in angioimmunoblastic T-cell lymphoma, Presented by: Caroline MacVicar

Caroline MacVicar

Molecular Residual Disease Detection via CAPP-Seq in Patients with PTCL Undergoing Autologous Stem Cell Transplantation, Presented by: Josie Ford

Josie Ford

Molecular Residual Disease Detection via CAPP-Seq in Patients with PTCL Undergoing Autologous Stem Cell Transplantation, Presented by: Josie Ford

Josie Ford

Molecular Residual Disease Detection via CAPP-Seq in Patients with PTCL Undergoing Autologous Stem Cell Transplantation, Presented by: Josie Ford

Josie Ford

Real-World Evidence for Devlisib and Romidepsin Combination in Patients with Relapsed/Refractory (R/R) Peripheral T-cell Lymphoma, Presented by: Josie Ford

Josie Ford

Real-World Evidence for Devlisib and Romidepsin Combination in Patients with Relapsed/Refractory (R/R) Peripheral T-cell Lymphoma, Presented by: Josie Ford

Josie Ford

Real-World Evidence for Devlisib and Romidepsin Combination in Patients with Relapsed/Refractory (R/R) Peripheral T-cell Lymphoma, Presented by: Josie Ford

Josie Ford

Study details

Our Study

Flow Chart

Study Sypnosis

News center

Consortium Highlights & Events

Publications

Social Media

For healthcare professionals

PIRT Calculator

Participating Sites Login

Study details

Our Study

Flow Chart

Study Sypnosis

News center

Consortium Highlights & Events

Publications

Social Media

For healthcare professionals

PIRT Calculator

Participating Sites Login

Study details

Our Study

Flow Chart

Study Sypnosis

News center

Consortium Highlights & Events

Publications

Social Media

For healthcare professionals

PIRT Calculator

Participating Sites Login

Publications

Publications

February, 2025

December 2024

American Society of Haematology Conference 2024

Oral presentations

Angela Koh

Angela Koh

Angela Koh

B. Poster presentations

Dimitra Karagkouni

Dimitra Karagkouni

Dimitra Karagkouni

Josie Ford

Josie Ford

Josie Ford

Makoto Iwasaki

Makoto Iwasaki

Makoto Iwasaki

October, 2024

July, 2024

Makoto Iwasaki

Makoto Iwasaki

Makoto Iwasaki

Shambhavi Singh

Shambhavi Singh

Shambhavi Singh

June 2024

T-cell Lymphoma Forum (TCLF) 2024

Oral presentations

Dr Salvia Jain

Dr Salvia Jain

Dr Salvia Jain

Mark Sorial

Mark Sorial

Mark Sorial

B. Poster presentations

Sean McCabe

Sean McCabe

Sean McCabe

Caroline MacVicar

Caroline MacVicar

Caroline MacVicar

Josie Ford

Josie Ford

Josie Ford

Josie Ford

Josie Ford

Josie Ford

Menu

Study details

News center

For healthcare professionals

Menu

Study details

News center

For healthcare professionals

Menu

Study details

News center

For healthcare professionals